Quinapril hydrochloride 10.832 mg (=10 mg quinapril base) - search results

sun pharmaceutical industries limited - quinapril hydrochloride (unii: 33067b3n2m) (quinapril - unii:rj84y44811) - quinapril hydrochloride 5 mg - hypertension quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. in using quinapril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk (see warnings). angioedema in black patients black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. quinapril hydrochloride tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous tr

United States - English - NLM (National Library of Medicine)

quinapril- quinapril hydrochloride tablet, film coated

proficient rx lp - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5) - quinapril 10 mg - hypertension quinapril tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, d

United States - English - NLM (National Library of Medicine)

quinapril- quinapril hydrochloride tablet, film coated

nucare pharmaceuticals, inc. - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5) - quinapril 20 mg - hypertension quinapril tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention,

United States - English - NLM (National Library of Medicine)

quinapril tablet

dr.reddy's laboratories limited - quinapril hydrochloride (unii: 33067b3n2m) (quinapril - unii:rj84y44811) - quinapril 5 mg - quinapril hydrochloride is indicated for the treatment of hypertension. it may be used alone or incombination with thiazide diuretics. in using quinapril hydrochloride, consideration should be given to the fact that another angiotensinconvertingenzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renalimpairment or collagen vascular disease. available data are insufficient to show that quinaprilhydrochloride does not have a similar risk (see warnings). black patients receiving ace inhibitor monotherapy have beenreported to have a higher incidence of angioedema compared to non-blacks. it should also be notedthat in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in blackpatients than in non-blacks. quinapril hydrochloride is contraindicated in patients who are hypersensitive to this product and inpatients with a history of angioedema related to previous treatment with an ace inhibitor.